Tuesday, September 26, 2023


Biotechnology News Magazine


Blacksmith Medicines Announces Merger with Forge Therapeutics

Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith: "Our target strategy is to focus on metalloenzymes of significant unmet need and high pharma interest, targets with validated biology that have been challenging to drug due to chemistry limitations that we can solve with our platform."

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

With SneakPeek, Myriad Genetics now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel® non-invasive prenatal screen, Foresight® carrier screen, and MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries.

Clinical Microbiomics Adds Metabolomics to Its Portfolio with Acquisition of MS-Omics

With this acquisition, Clinical Microbiomics adds leading expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.  

Myonex Completes Acquisition of Hubertus Clinical Trial and Packaging Business

“The new Berlin location strengthens our capabilities and resources inside the EU for both packaging and sourcing, including decentralized trials,” said James Lovett, Chief Executive Officer at Myonex.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

Avance Clinical has backing from private equity group Riverside Company for their global expansion program.